AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 25434365
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (control group) administered at corresponding time points
Trial: 21592110
Drug: Deferasirox (Exjade),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deferasirox (Exjade), average dose 19.4 ± 6.3 mg/kg per day
Trial: 19116326
Drug: High polyunsaturated
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High polyunsaturated fat intake (>9.9 g/d) with higher α-tocopherol concentrations
Trial: 9246969
Drug: CAPF chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAPF chemotherapy alone (control)
Trial: 29258541
Drug: Intravenous iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous iron polymaltose (single dose calculated using the Ganzoni formula)
Trial: 25683075
Drug: Internet-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based treatment programme (n = 124)
Trial: 25683075
Drug: Postal treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postal treatment programme (n = 126)
Trial: 20026777
Drug: Bivalirudin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bivalirudin plus a glycoprotein IIb/IIIa inhibitor
Trial: 17691578
Drug: Control (medication,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (medication, manicol/beronald, Ca2+ antagonist, citicoline, etc.)
Trial: 15338488
Drug: COBRA therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COBRA therapy (prednisolone, methotrexate, and sulfasalazine)
Trial: 11919306
Drug: Enoxaparin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin (40 mg subcutaneously daily for 6 to 10 days followed by enoxaparin for another 21 days)
Trial: 11919306
Drug: Placebo (after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (after initial enoxaparin treatment)
Trial: 8087360
Drug: Thiorphan (1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiorphan (1.25 mg)
Trial: 2697584
Drug: Various drug
RxNorm normalized name: VARIOUS DRUG CLASSES IN ATC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various drug combinations
Trial: 2697584
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of adriamycin, carmustine, cyclophosphamide, and melphalan
Trial: 25323140
Drug: Medication (nortriptyline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication (nortriptyline v. venlafaxine)
Trial: 21654506
Drug: Creatine monohydrate
RxNorm normalized name: Creatine Monohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine monohydrate (CMH) 200 mg/kg daily for 6 months
Trial: 19536164
Drug: Nutritional intervention
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional intervention offered as an adjunct to smoking cessation programmes
Trial: 8229908
Drug: Sodium loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium loading (10 g/day)
Trial: 21224376
Drug: Sorafenib 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib 400 mg BID daily
Trial: 11980131
Drug: Allicor 2400
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Allicor 2400 mg/day
Trial: 11980131
Drug: Kwai 900
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Kwai 900 mg/day
Trial: 9481530
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (5 mg elemental zinc in syrup daily for 12 weeks)
Trial: 9481530
Drug: Placebo (syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (syrup only)
Trial: 25830
Drug: 180 ml
RxNorm normalized name: Glutol, 100 g/180 mL oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 180 ml 100 proof vodka
Trial: 25830
Drug: 180 ml
RxNorm normalized name: Glutol, 100 g/180 mL oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 180 ml water
Trial: 27912934
Drug: Traditional Chinese
RxNorm normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Chinese Medicine (TCM) treatment administered twice daily for 7-21 days, followed by TCM for AECOPD risk window over 28 days.
Trial: 27912934
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment administered according to the assigned group.
Trial: 27912934
Drug: TCM treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TCM treatment
Trial: 27912934
Drug: Both TCM
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both TCM and conventional treatments
Trial: 26241543
Drug: Mucosolvan (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mucosolvan (90 mg/day aerosol + 180 mg/day intravenous for 8 days)
Trial: 18262663
Drug: Dopamine D3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine D3 receptor antagonism
Trial: 18262663
Drug: New compounds
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New compounds targeting corticotropin‐releasing factor signalling and the endocannabinoid system
Trial: 16603599
Drug: DCb (docetaxel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DCb (docetaxel 75 mg/m(2), carboplatin AUC 6)
Trial: 16603599
Drug: MIC/MVP (mitomycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MIC/MVP (mitomycin 6 mg/m(2), ifosfamide 3 g/m(2) and cisplatin 50 mg/m(2) or mitomycin 6 mg/m(2), vinblastine 6 mg/m(2) and cisplatin 50 mg/m(2))
Trial: 1450706
Drug: Recombinant alpha
RxNorm normalized name: Recombinant alpha glucosidase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant alpha interferon (IFN, 3 MU daily for 10 days followed by 3 MU twice/week for 3 months)
Trial: 31570394
Drug: AT-527 600
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AT-527 600 mg once daily for seven days
Trial: 29534063
Drug: Clinical Decision
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical Decision Support (CDS) tool for anticoagulant therapy adherence
Trial: 23070486
Drug: Rilonacept (2.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rilonacept (2.2 mg/kg, maximum 160 mg) by weekly subcutaneous injection for two 3-month courses
Trial: 21073556
Drug: Proton Pump
RxNorm normalized name: Proton pump inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton Pump Inhibitors (PPIs) like omeprazole and esomeprazole
Trial: 21073556
Drug: NSAIDs that
RxNorm normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NSAIDs that do not interact with aspirin
Trial: 16100136
Drug: Gentamicin 240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin 240 mg IV once daily
Trial: 9852390
Drug: GnRHa +
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRHa + add-back therapy (20 microg of ethinyl estradiol with 0.15 mg desogestrel)
Trial: 10621763
Drug: Fluoxetine (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (up to 60 mg/day)
Trial: 2200195
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (radio- and chemotherapy with prospidine)
Trial: 2200195
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (vestibular cord cancer stage II)
Trial: 31733423
Drug: Teriparatide (TPTD)
RxNorm normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Teriparatide (TPTD) 20 μg, s.c., once daily
Trial: 31733423
Drug: Percutaneous vertebroplasty
RxNorm normalized name: PERCUTANEOUS INTRODUCER SET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Percutaneous vertebroplasty (PVP) plus alendronate (70 mg, p.o., once weekly)
Trial: 31733423
Drug: Cost of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cost of TPTD treatment
Trial: 31733423
Drug: Cost of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cost of PVP treatment
Trial: 28088167
Drug: ARMS-I (Halo™),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARMS-I (Halo™), sprayed intra-orally 3 times daily for 75 days
Trial: 25449059
Drug: Inhaled tiotropium
RxNorm normalized name: tiotropium Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled tiotropium 18 μg once daily for 1 month (n = 10)
Trial: 25449059
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no treatment, n = 10)
Trial: 23706946
Drug: Pro re
RxNorm normalized name: Blistex Pro Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pro re nata dosing
Trial: 19080748
Drug: Minimally invasive
RxNorm normalized name: SPY Minimally Invasive Surgery (SPY-MIS) Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimally invasive neurosurgery or intravenous hemostatics
Trial: 19080748
Drug: Optimized medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimized medical care according to ICH treatment guidelines
Trial: 17173226
Drug: Dexamethasone (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (10 mg every 6 hours)
Trial: 9602314
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy (24 Gy in four fractions of 6 Gy)
Trial: 2897978
Drug: Suriclone 0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suriclone 0.8 mg
Trial: 2897978
Drug: Suriclone 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suriclone 0.2 mg
Trial: 2897978
Drug: Suriclone 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suriclone 0.6 mg
Trial: 22576074
Drug: 0.15 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.15 mg/kg intravenous ketamine
Trial: 22576074
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg rectal diclofenac suppository
Trial: 20490573
Drug: Gabapentin 600
RxNorm normalized name: gabapentin 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin 600 mg (G2) or placebo (G1 and G3) administered 2 hours prior to surgery and in the PACU
Trial: 20490573
Drug: Gabapentin 600
RxNorm normalized name: gabapentin 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin 600 mg (G3)
Trial: 28560658
Drug: Pradefovir 10
RxNorm normalized name: Pradefovir
DrugBank: Pradefovir (DB15550)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pradefovir 10 mg
Trial: 16239358
Drug: Food effect
RxNorm normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Food effect at 30 mg
Trial: 11194526
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g of American ginseng (AG)
Trial: 11194526
Drug: 6 g
RxNorm normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 g of American ginseng (AG)
Trial: 11194526
Drug: 9 g
RxNorm normalized name: Publix Pen Needle 29 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9 g of American ginseng (AG)
Trial: 11194526
Drug: Placebo (0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0 g of AG)
Trial: 9278463
Drug: Calcium and
RxNorm normalized name: Calcium and Magnesium
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium and Vitamin D supplementation (500 mg of calcium plus 700 IU of vitamin D3 per day)
Trial: 28637449
Drug: Enhanced treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced treatment as usual (E-TAU), facilitated referral to specialized mental health care
Trial: 23052650
Drug: Vitamin A
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin A supplementation with antibiotics (n=17)
Trial: 23052650
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E supplementation with antibiotics (n=18)
Trial: 23052650
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (antibiotics only; n=25)
Trial: 22077144
Drug: Apixaban (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apixaban (2.5 mg orally twice daily for 30 days)
Trial: 22077144
Drug: Enoxaparin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin (40 mg subcutaneously once daily for 6 to 14 days)
Trial: 2821784
Drug: Nedocromil sodium
RxNorm normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nedocromil sodium (other doses)
Trial: 31240312
Drug: 240 g
RxNorm normalized name: aspirin 15.6 GM (240 grains) Oral Bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 240 g banana + 150 mL control drink
Trial: 31240312
Drug: 250 mL
RxNorm normalized name: TPN Bag 250 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mL control drink (Fresubin 2 kcal fiber, neutral flavor)
Trial: 29231539
Drug: Basic pharmaceutical
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic pharmaceutical treatment and swallowing rehabilitation (Control group)
Trial: 26697847
Drug: Donepezil (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil (5 mg to 10 mg over 6 weeks)
Trial: 23647738
Drug: Vx-001 +
RxNorm normalized name: VX-001 component TERT-572
DrugBank: TERT-572 (DB17286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vx-001 + Montanide ISA51 VG (2 mg, subcutaneously)
Trial: 21200319
Drug: C-MB-P lock
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C-MB-P lock solution (0.24 M sodium citrate, 0.15% methylene blue, 0.15% methylparaben, 0.015% propylparaben)
Trial: 21200319
Drug: C-MB-P lock
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C-MB-P lock solution
Trial: 21200319
Drug: Heparin (5000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin (5000 units of unfractionated heparin)
Trial: 11021731
Drug: 0.25 mg
RxNorm normalized name: biotin 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg butorphanol tartrate (n = 31)
Trial: 11021731
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg butorphanol tartrate (n = 29)
Trial: 11021731
Drug: 1.0 mg
RxNorm normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg butorphanol tartrate (n = 30)
Trial: 11021731
Drug: 2.0 mg
RxNorm normalized name: LORAZEPAM 2.0 mg in 1 mL INTRAVENOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0 mg butorphanol tartrate (n = 30)
Trial: 3518329
Drug: Phosphatidylserine (BS-PS)
RxNorm normalized name: Phosphatidylserine
DrugBank: Phosphatidyl serine (DB00144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phosphatidylserine (BS-PS) 3 X 100 mg for six weeks
Trial: 30200906
Drug: Exposure to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure to bright white light therapy
Trial: 26827289
Drug: GSK1278863 (10,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK1278863 (10, 25, 50, or 100 mg)
Trial: 26827289
Drug: GSK1278863 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK1278863 (10 or 25 mg)
Trial: 17081815
Drug: GLP-2 (1.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLP-2 (1.6 mg)
Trial: 17081815
Drug: GLP-2 (3.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLP-2 (3.2 mg)
Trial: 11943529
Drug: Clo‐eye G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clo‐eye G (30 microg peribulbar clonidine)
Trial: 11943529
Drug: CG (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CG (oral saline and peribulbar saline)
Trial: 8133101
Drug: Dexamethasone 0.15
RxNorm normalized name: dexamethasone 0.15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 0.15 mg/kg iv every 6 h for 2 days
Trial: 8133101
Drug: Dexamethasone 0.15
RxNorm normalized name: dexamethasone 0.15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 0.15 mg/kg iv every 6 h for 4 days
Trial: 2697955
Drug: Nadolol (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nadolol (mean dose 87 mg/day)
Trial: 2697955
Drug: Propranolol (dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (dose 144 mg/day)
Trial: 2697955
Drug: Nadolol (doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nadolol (doses less than 200 mg/day)
Trial: 2697955
Drug: Nadolol (doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nadolol (doses of 240 and 280 mg/day)
Trial: 241365
Drug: Kö 1366
RxNorm normalized name: niacin
DrugBank: Niacin (DB00627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kö 1366 (0.0375 mg/kg)
Trial: 241365
Drug: Practolol (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Practolol (0.3 mg/kg)
Trial: 20441243
Drug: Atorvastatin (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (30 mg/day for at least 8 weeks)
Trial: 20441243
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no atorvastatin therapy)
Trial: 17285097
Drug: Amitriptyline (50-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline (50-100 mg daily)
Trial: 16830653
Drug: BCG vaccine
RxNorm normalized name: BCG Vaccine
DrugBank: BCG vaccine (DB12768)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCG vaccine (105 live bacilli/per dose) with 12 months M.D.T.‐MBR
Trial: 16830653
Drug: Mw vaccine
RxNorm normalized name: polyethyloxazoline (200000 MW)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mw vaccine (1 x 108 killed bacilli as first dose and 0.5 x 108/dose in subsequent doses) with 12 months M.D.T.‐MBR
Trial: 9220214
Drug: Buspirone 15
RxNorm normalized name: busPIRone 15 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buspirone 15 mg BID
Trial: 9220214
Drug: Buspirone 10
RxNorm normalized name: busPIRone 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buspirone 10 mg TID
Trial: 10356651
Drug: Buspirone 15
RxNorm normalized name: busPIRone 15 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buspirone 15 mg BID and TID
Trial: 7605020
Drug: Low-dose isoflurane
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose isoflurane (0.5 MAC)
Trial: 7605020
Drug: Low-dose desflurane
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose desflurane (0.5 MAC)
Trial: 7605020
Drug: High-dose propofol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose propofol (200 micrograms.kg‐1.min‐1)
Trial: 7605020
Drug: Low-dose propofol
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose propofol (0.5 MAC)
Trial: 1899823
Drug: High-nitrogen, isotonic,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-nitrogen, isotonic, enteral feeding solution (Osmolite HN, pH = 6.4) (n = 7)
Trial: 30634590
Drug: Daily nutritional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily nutritional supplementation with vitamin D₃ (5000 IU) and phenylbutyrate (PBA, 2 × 500 mg)
Trial: 28045352
Drug: Antidepressant prescribed
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant prescribed to older adults without MDD
Trial: 28045352
Drug: Antidepressant prescribed
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant prescribed to older adults with MDD
Trial: 22752690
Drug: cilengitide 240
RxNorm normalized name: Cilengitide
DrugBank: Cilengitide (DB11890)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cilengitide 240 mg/m(2) twice weekly
Trial: 22752690
Drug: cilengitide 400
RxNorm normalized name: Cilengitide
DrugBank: Cilengitide (DB11890)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cilengitide 400 mg/m(2) twice weekly
Trial: 22752690
Drug: cilengitide 600
RxNorm normalized name: Cilengitide
DrugBank: Cilengitide (DB11890)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cilengitide 600 mg/m(2) twice weekly
Trial: 22752690
Drug: docetaxel 75
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: docetaxel 75 mg/m(2) once every 3 weeks
Trial: 22333175
Drug: Etanercept 50
RxNorm normalized name: etanercept 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept 50 mg once-weekly subcutaneous injection
Trial: 19587338
Drug: Raxibacumab (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raxibacumab (40 mg/kg)
Trial: 9048390
Drug: No prophylactic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No prophylactic antibiotics (Control)
Trial: 15084930
Drug: Tacrolimus (0.1+/‐0.004
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tacrolimus (0.1+/‐0.004 mg/kg/d)
Trial: 7785746
Drug: Nedocromil sodium
RxNorm normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nedocromil sodium 2% eye drops, administered four times daily (n=153) for VKC